China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome to develop the latter’s preclinical monoclonal antibody, MAb11-22.1, for antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR)-T cell therapies. The deal follows Northeast’s 2017 in-licensing of a Herceptin biosimilar from MedAbome.
Collaboration Terms
Under the agreement, MedAbome will provide Northeast with MAb11-22.1 and proprietary technology to develop ADCs and CAR-T therapies. Northeast will handle IND and NDA filings for resulting products in markets outside the U.S., Canada, and Mexico, while MedAbome will assist in building R&D, production, and quality control platforms. Financial terms include USD 6 million and RMB 6 million (USD 865,700) upfront, plus USD 7 million and RMB 7 million (USD 1 million) in milestone payments and sales royalties.
Preclinical Data and Patents
MAb11-22.1 has demonstrated efficacy and safety in tumor growth inhibition studies and animal toxicology models. MedAbome has filed U.S. and PCT patents for the candidate, positioning it for global development.
trategic Outlook
The partnership expands Northeast’s pipeline into next-gen oncology therapies, leveraging MedAbome’s antibody expertise. The deal underscores growing China-U.S. biotech collaborations in targeted cancer treatments.-Fineline Info & Tech
